Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease

• Published in: Zhong hua yi xue za zhi Vol. 104; no. 18; p. 1601
• Main Authors: Bi, Z K, Xu, Y, Guo, L, Zhang, W J, You, Y T, Li, J W, Zhao, C L, Shan, Y F, Xia, T T, Li, Y F, Xu, Z, Fan, Y, Bai, L
• Format: Journal Article
• Language: Chinese
• Published: China 14.05.2024
• Subjects: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung - therapy; Female; Humans; Immunotherapy; Inflammation; Interleukin-6 - blood; Interleukin-8 - blood; Lung Neoplasms - blood; Lung Neoplasms - therapy; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive - blood; Pulmonary Disease, Chronic Obstructive - therapy; Retrospective Studies; Tumor Necrosis Factor-alpha - blood
• ISSN: 0376-2491
• DOI: 10.3760/cma.j.cn112137-20231130-01247

To investigate the impact of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD). A retrospective cohort study was performed to include 178 patients with Ⅲ-Ⅳ NSCLC complicated with COPD who received at least 2 times of immunotherapy in Xinqiao Hospital of the Army Medical University from January 2019 to August 2021. Baseline peripheral blood inflammatory indicators such as interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α) were collected within 2 weeks before the first treatment, with the last one being on or before February 7, 2022. X-tile software was used to determine the optimal cut-off value of peripheral blood inflammatory indicators. The Cox multivariate regression models were used to analyze the factors affecting progression free survival (PFS) and overall survival (OS). Among the 178 patients, there were 174 males (97.8%) and 4 femal